# TEST REQUISITION FORM

For fastest order processing, order online at http://www.foundationmedicine.com
Other options: Email *(recommended)* client.services@foundationmedicine.com or Fax to 617.418.2290
**IF REQUIRED FIELDS ARE NOT PROVIDED, TESTING MAY BE DELAYED.**

**For Foundation Medicine Use Only**

## PATIENT INFORMATION

First Name | MI | Last Name | Medical Record # | DOB *(MM/DD/YYYY)* | Sex ☐ F ☐ M

Address | City | State | Postal Code | Country | Primary Phone

## CURRENT DIAGNOSIS/PATIENT HISTORY

Primary ICD-10 (C&D codes only) | Stage

Prior/Current Targeted Therapies *(optional)*

**Patient has received transplant?** ☐ Yes ☐ No

**Diagnosis:**
☐ Colorectal Carcinoma ☐ Melanoma
☐ Breast ☐ NSCLC ☐ Ovarian
☐ Prostate ☐ Other _____

**Disease Status** *(select all that apply)*:
☐ Metastatic ☐ Recurrent
☐ Refractory ☐ Relapse
☐ None ☐ Progression

**Attachments:** ☐ Copy of recent pathology/cytology reports including (if available), CBC/differential, BMA differential, FAB classification. ☐ Test results from all other Molecular Diagnostic Assays by FISH, IHC, or other genetic assays, e.g., *ER, PR, HER2, EGFR, KRAS,* etc.

## TREATING PHYSICIAN INFORMATION (Please provide best contact information for case follow-up)

Facility Name | Treating Physician *(full legal name)*

Facility Address | City | State | Postal Code | Country

Foundation Medicine Account # *(optional)* | Email | Phone | Fax

Additional Physician to be Copied *(optional)* | Facility Name *(optional)* | Email *(optional)* | Fax *(optional)*

## TEST MENU | Test/Laboratory Developed Test (LDT) Selection

| *Genomic Test* | *Description* | *Accepted Specimen Type* |
|---|---|---|
| ☐ **FoundationOne®CDx** | FDA-approved companion diagnostic for solid tumors | FFPE Tissue |
| ☐ **FoundationOne®Liquid CDx** | FDA-approved companion diagnostic for solid tumors | Peripheral Whole Blood |
| ☐ **If specimen submitted is insufficient for analysis, use portfolio reflex option** *(see back for details)* | | |
| ☐ **FoundationOne®Heme** | LDT RNA & DNA sequencing for heme malignancies, sarcomas or solid tumors | Peripheral Whole Blood, Bone Marrow Aspirate, FFPE Tissue, Extracted Nucleic Acid |
| ☐ **Specimen has or is undergoing other NGS testing** | | |

*Additional Option:*

☐ **IHC Testing PD-L1** *(see back for details)* — FFPE tissue

## SPECIMEN RETRIEVAL | Provide all information required per sample type

Submitting Pathologist Name | Pathology Lab Name | Email | Phone | Fax

☐ **I am requesting a specific specimen** ☐ **I will let the pathologist choose the specimen** ☐ **I am providing FFPE block return address on back of form**

Date of Collection *(MM/DD/YYYY)* | Specimen ID | Site of Biopsy | Alternate Choice *(optional)*

☐ **FFPE Tissue**
- ☐ **I will arrange for specimen shipment**
- ☐ **Contact the pathology lab to obtain specimen**

☐ **Peripheral Whole Blood**
- ☐ **I will arrange for specimen shipment**
- ☐ **Mobile Phlebotomy requested** *(see guidelines on website)*

☐ **Bone Marrow Aspirate/Extracted Nucleic Acid**
- ☐ **Ordering Facility responsible for shipment**

## BILLING INFORMATION | Select one of the three payment options and complete all fields indicated *(Asterisk indicates Medicare requirement)*

☐ **Insurance** *(check one):* ☐ *** Medicare** ☐ *** ABN Attached** ☐ **Medicare Advantage** ☐ **Other** **Plan Name** _____

Policy # | Group # | Prior Authorization #

☐ **Self-Pay:** Contact Name | Email | Phone

*** Patient status at time of specimen collection:**
☐ **Office** (non-hospital) ☐ **Outpatient**
☐ **Inpatient** *(requires Discharge Date below MM/DD/YYYY)*
_____ ***OR*** ☐ **Not yet discharged**

☐ **Facility:** Address | City | State | Postal Code | Country ☐ Same as Treating Physician

## CERTIFICATE OF MEDICAL NECESSITY/CONSENT/TEST AUTHORIZATION AND PHYSICIAN SIGNATURE

My signature constitutes a Certificate of Medical Necessity, certifies that this test information will inform the patient's ongoing treatment plan, and certifies that I am the patient's treating physician. I have explained to the patient the nature and purpose of the testing to be performed and have obtained informed consent, to the extent legally required, to permit Foundation Medicine to **(a)** perform the testing specified herein, **(b)** retain the test results for an indefinite period for internal quality assurance/operations purposes, **(c)** de-identify the test results and use or disclose such de-identified results for future unspecified research or other purposes, and **(d)** release the test results to the patient's third-party payer as needed for reimbursement purposes.

My signature also authorizes Foundation Medicine to select the most appropriate test (pursuant to Foundation Medicine's Change in Test Authorization Policy) based on requisition/pathology information.

Treating Physician Signature | Printed Name *(Full legal name)* | Date *(MM/DD/YYYY)*

FOUNDATION MEDICINE®


www.foundationmedicine.com | Tel +1.888.988.3639 | Fax +1.617.418.2290

## FFPE BLOCK RETURN INFORMATION

FFPE Block Return Address

City | State | Postal Code | Country

Email | Phone | Fax

## OTHER INFORMATION

**For information on ICD codes**, visit this website:
*https://icd10cmtool.cdc.gov/*

**Portfolio Reflex Option:**
If the "Portfolio Reflex" checkbox is selected, we will proceed with the initial NGS test selected and if the specimen does not meet the criteria for successful testing, we will automatically reflex to the other test detailed below and procure a new specimen. The failed test is not billed, and the successful test will be billed according to our standard practices. Please see https://www.foundationmedicine.com/genomic-testing/order for more information.

**Additional Case Information** *(optional)*

## TECHNICAL INFORMATION

### FOUNDATION**ONE**®**CDx**

FoundationOne®CDx is a qualitative next-generation sequencing based *in vitro* diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit *http://www.F1CDxLabel.com*

### FOUNDATION**ONE**®**LIQUID CDx**

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based *in vitro* diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if available. For the complete label, including companion diagnostic indications and complete risk information, please visit *http://www.F1LCDxLabel.com*

### FOUNDATION**ONE**®**HEME**

**About the Test** FoundationOne®Heme is a laboratory developed test that combines DNA sequencing of 406 genes and RNA sequencing of 265 genes for patients with hematologic malignancies, sarcomas or solid tumors where sensitive fusion detection is desired. The test can be used by physicians to identify potential targeted therapy options, detect alterations in prognostic genes, and sub-classify sarcoma diagnoses. For more information on FoundationOne Heme, please see its Technical Specifications at *http://www.foundationmedicine.com/heme*

### IHC Testing

Scoring and clone utilization for PD-L1 testing is based on FDA-approved indications. Refer to *https://www.foundationmedicine.com/genomic-testing/order* for information.

## MEDICARE COVERAGE SUMMARY *(Foundation Medicine tests may be covered by Original Medicare[1] and Medicare Advantage[2])*

| TEST | CONDITIONS FOR MEDICARE COVERAGE | PATIENT COVERAGE CRITERIA |
|---|---|---|
| **FoundationOne®CDx** | Covered[3] if all patient coverage criteria are met. ABN required if patient does not meet the patient coverage criteria or if person ordering the test is not a treating physician[4]. | i) Patient has been diagnosed with a solid malignant neoplasm; ***AND***<br>ii) Patient has either recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer (only requires one of these to be met); ***AND***<br>iii) Patient has not been previously tested with the same test using NGS for the same cancer genetic content[6]; ***AND***<br>iv) Patient has decided to seek further cancer treatment (e.g., therapeutic chemotherapy) |
| **FoundationOne®Liquid CDx** | | |
| **FoundationOne®Heme** | Covered[5] if all patient coverage criteria are met. ABN required if patient does not meet the patient coverage criteria or if person ordering the test is not a treating physician[4]. | i) Patient has been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN); ***OR***<br>ii) Patient has a suspected myeloid malignancy with an undefined cytopenia for greater than 4 months, and other possible causes have been reasonably excluded<br>***AND (both criteria iii and iv below)***<br>iii) Patient has not previously received or is not currently receiving NGS testing on the specimen for which the test is currently being ordered<br>iv) Patient has not been tested with the same test for the same genetic content[6] |


**References**

1. Medicare administered by federal government.
2. Medicare administered by private insurers.
3. Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R – reference appendix B)
4. A "treating physician" is a physician, as defined in §1861(r) of the Social Security Act, who furnishes a consultation or treats a beneficiary for a specific medical problem, and who uses the results of a diagnostic test in the management of the beneficiary's specific medical problem. More information is available at ***https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R80BP.pdf***.
5. MolDx Local Coverage Determination (LCD): Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38047)
6. Repeat testing (FoundationOne®CDx, FoundationOne®Liquid CDx, or FoundationOne®Heme) after disease progression (i.e., there is evidence of a new malignant growth despite response to a prior targeted therapy) may be covered under the NCD for qualifying Medicare beneficiaries.




www.foundationmedicine.com | Tel +1.888.988.3639 | Fax +1.617.418.2290